Principal Investigator
Alejandra Perez
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230138
Clinical Trial Summary
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Breast Cancer
Contact Information
Phone Number
305-243-2647